Please ensure Javascript is enabled for purposes of website accessibility

Why Intersect ENT Shares Are Rallying 17% Today

By Todd Campbell – May 3, 2017 at 2:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

First-quarter financial results are fueling investor optimism.

What happened

Intersect ENT (XENT) shares are up 17% at 2:15 p.m. EDT today after management reported first-quarter financial results and boosted its outlook for the rest of the year.

So what

Last fall, Intersect ENT's shares fell on worry that changes to reimbursement rules from the Centers for Medicare & Medicaid Services (CMS) applying to upper airway procedures could crimp sales this year.

A man sitting with his back against the wall as money falls from the sky around him.


Yesterday, Intersect ENT's management overcame some of those concerns by delivering better than expected first-quarter financial results. 

Specifically, revenue was $20.5 million in the first quarter, up 23% from the first quarter of 2016, gross margin climbed 5% to 86% year over year in the quarter, and its net loss improved to $0.23 per share from $0.29 in the same period last year.

Top-line growth came from rising demand for Intersect ENT's Propel and Propel mini sinus products, higher average selling prices, and post-launch sales from its recently FDA approved Propel Contour, a less costly and less invasive solution for patients suffering from recurrent sinus obstruction who have had ethmoid sinus surgery.

Now what

Intersect now expects full-year sales of between $89 to $91 million, up from prior guidance for sales of $87 million to $89 million. Operating expenses are anticipated to be within the range of $96 million to $98 million.

Although the company's guidance suggests it will lose money this year, Intersect ENT appears to be making progress toward profitability, and it has plenty of cash still in the bank. Exiting March, its cash position stands at $98.4 million. 

Assuming Intersect ENT can limit the risk of pricing pressure (perhaps via getting its own CMS J-code for payment), then this stock could end up being a bargain-bin buy sometime next year.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intersect ENT Stock Quote
Intersect ENT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.